GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (LTS:0KCC) » Definitions » Institutional Ownership

OncoCyte (LTS:0KCC) Institutional Ownership : 3.36% (As of Jun. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is OncoCyte Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, OncoCyte's institutional ownership is 3.36%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, OncoCyte's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, OncoCyte's Float Percentage Of Total Shares Outstanding is 98.78%.


OncoCyte Institutional Ownership Historical Data

The historical data trend for OncoCyte's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Institutional Ownership Chart

OncoCyte Historical Data

The historical data trend for OncoCyte can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 7.96 8.14 6.21 6.23 6.10 6.10 5.85 5.70 3.38 3.36

OncoCyte Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


OncoCyte (LTS:0KCC) Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (LTS:0KCC) Headlines

No Headlines